Pfizer has stopped development of its cholesterol drug torcetrapib, due to safety concerns. According to the company, an independent safety board recommended the discontinuation of the clinical trial, Illuminate, because of an imbalance of mortality and cardiovascular events. Pfizer immediately terminated the entire development program for the drug. The product, which raises levels of “good” HDL cholesterol, was expected to be a major growth driver for the company, with sales potenti...